凯尼克萨制药
KNSA
78.59
-1.35
-1.69%
凯尼克萨制药
US · KNSA
#1938 按市值排名
上市于 2018
78.59
-1.35
-1.69%
实时 - 追踪5344个代码 - 心跳于324秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了5家。
- 机构持股总比例下降了1.0个百分点。
机构持股
- 机构持股比例
- 61.53% -0.96pp
- 机构数量
- 326 +5
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund41.01%
Hedge Fund14.86%
Individual/Insider4.35%
Public Company2.58%
Private Company1.47%
VC/PE Fund0.69%
Government Pension Fund0.63%
Insurance Company0.13%
Bank/Investment Bank0.11%
Other34.18%
主要股东 截至 2026-06-30
FMR
8.93% · 6.97M 股
Rubric Capital Management LP
5.13% · 4.00M 股
Baker Bros. Advisors LP
3.63% · 2.83M 股
BlackRock
3.51% · 2.74M 股
Tang Capital Management, LLC
2.90% · 2.26M 股
Vanguard Portfolio Management, LLC
2.45% · 1.91M 股
Sanjiv Patel
2.35% · 1.83M 股
Vanguard Capital Management, LLC
1.84% · 1.43M 股
Robert Desnick
1.63% · 1.27M 股
Morgan Stanley
1.28% · 1.00M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 40次买入 · 10次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Sanjiv Patel | Chairperson & CEO | 2.35% |
| John Paolini | Senior VP & Chief Medical Officer | 0.09% |
| Michael Megna | Chief Accounting Officer & Group VP of Finance | 0.04% |
| Eben Tessari | Senior Vice President | 0.03% |
| Richard Levy | Independent Director | 0.03% |
| Mark Ragosa | Senior Vice President | 0.03% |
| Ross Moat | Chief Commercial Officer | 0.02% |
| Tracey McCain | Independent Director | 0.02% |
| Kimberly Popovits | Independent Director | 0.02% |
| Thomas Malley | Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-02 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Derivative Exercise and Sale | -10,131 | $79.28–80.30 |
| 2026-09-02 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Intent to Sell (Form 144) | -4,600 | $80.30 |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Derivative Exercise and Sale | -15,144 | $79.28 |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Other Derivative Acquisition | +30,050 | -- |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Other Derivative Acquisition | +120,150 | $79.28 |
| 2026-08-31 | Sanjiv Patel | Chairperson & CEO | Derivative Exercise and Retained | +16,174 | -- |
| 2026-08-31 | John Paolini | Senior VP & Chief Medical Officer | Derivative Exercise and Sale | -4,029 | $79.28 |
| 2026-08-31 | John Paolini | Senior VP & Chief Medical Officer | Other Derivative Acquisition | +6,700 | -- |
| 2026-08-31 | John Paolini | Senior VP & Chief Medical Officer | Other Derivative Acquisition | +26,750 | $79.28 |
| 2026-08-31 | John Paolini | Senior VP & Chief Medical Officer | Derivative Exercise and Retained | +4,299 | -- |
| 2026-08-31 | Mark Ragosa | Senior Vice President | Derivative Exercise and Sale | -4,404 | $79.28 |
| 2026-08-31 | Mark Ragosa | Senior Vice President | Other Derivative Acquisition | +7,800 | -- |
| 2026-08-31 | Mark Ragosa | Senior Vice President | Other Derivative Acquisition | +31,150 | $79.28 |
| 2026-08-31 | Mark Ragosa | Senior Vice President | Derivative Exercise and Retained | +4,700 | -- |
| 2026-08-31 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Other Derivative Acquisition | +3,650 | -- |
| 2026-08-31 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Other Derivative Acquisition | +14,600 | $79.28 |
| 2026-08-31 | Michael Megna | Chief Accounting Officer & Group VP of Finance | Derivative Exercise and Retained | +1,365 | -- |
| 2026-08-31 | Ross Moat | Chief Commercial Officer | Derivative Exercise and Sale | -4,007 | $79.28 |
| 2026-08-31 | Ross Moat | Chief Commercial Officer | Other Derivative Acquisition | +9,250 | -- |
| 2026-08-31 | Ross Moat | Chief Commercial Officer | Other Derivative Acquisition | +36,950 | $79.28 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
凯尼克萨制药 讨论区 0 条评论